A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Trial Profile

A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Liposarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as per ClinicalTrials.gov record.
    • 25 Apr 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.
    • 10 Oct 2013 Planned number of patients changed from 76 to 86 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top